US5977144A
(en)
*
|
1992-08-31 |
1999-11-02 |
University Of Florida |
Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
|
US7214686B2
(en)
|
1997-06-30 |
2007-05-08 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
US6632823B1
(en)
*
|
1997-12-22 |
2003-10-14 |
Merck & Co., Inc. |
Substituted pyridine compounds useful as modulators of acetylcholine receptors
|
US6277870B1
(en)
|
1998-05-04 |
2001-08-21 |
Astra Ab |
Use
|
FR2804430B1
(fr)
*
|
2000-01-28 |
2002-03-22 |
Sanofi Synthelabo |
Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
|
GB0010955D0
(en)
|
2000-05-05 |
2000-06-28 |
Novartis Ag |
Organic compounds
|
US8914114B2
(en)
|
2000-05-23 |
2014-12-16 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
US6479510B2
(en)
|
2000-08-18 |
2002-11-12 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
US6486172B2
(en)
|
2000-08-18 |
2002-11-26 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
WO2002016356A2
(en)
*
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
AU2001282875A1
(en)
|
2000-08-21 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
WO2002016355A2
(en)
*
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
|
WO2002015662A2
(en)
*
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
|
PE20021019A1
(es)
|
2001-04-19 |
2002-11-13 |
Upjohn Co |
Grupos azabiciclicos sustituidos
|
AR036041A1
(es)
*
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
BR0212101A
(pt)
|
2001-08-24 |
2004-08-24 |
Pharmacia & Up John Company |
7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
|
EP1419162A1
(en)
*
|
2001-08-24 |
2004-05-19 |
Pharmacia & Upjohn Company |
Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease
|
DE60218493D1
(de)
*
|
2001-09-12 |
2007-04-12 |
Pharmacia & Upjohn Co Llc |
Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
|
KR100614900B1
(ko)
*
|
2001-10-02 |
2006-08-25 |
파마시아 앤드 업존 캄파니 엘엘씨 |
질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물
|
US6849620B2
(en)
|
2001-10-26 |
2005-02-01 |
Pfizer Inc |
N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
|
WO2003040147A1
(en)
|
2001-11-08 |
2003-05-15 |
Pharmacia & Upjohn Company |
Azabicyclic-substituted-heteroaryl compounds for the treatment of disease__________________________________________________________________________________________________________________________
|
EP1442037A1
(en)
|
2001-11-09 |
2004-08-04 |
PHARMACIA & UPJOHN COMPANY |
Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
|
NZ554913A
(en)
|
2001-12-14 |
2009-01-31 |
Targacept Inc |
Methods and compositions for the treatment of central nervous system disorders
|
DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
MXPA04007936A
(es)
|
2002-02-15 |
2004-11-26 |
Upjohn Co |
Compuestos de aril-sustituidos para el tratamiento de enfermedades.
|
EP1476448A2
(en)
*
|
2002-02-19 |
2004-11-17 |
PHARMACIA & UPJOHN COMPANY |
Azabicyclic compounds for the treatment of disease
|
AU2003219690A1
(en)
*
|
2002-02-19 |
2003-09-09 |
Pharmacia And Upjohn Company |
Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
|
JP2005525357A
(ja)
*
|
2002-02-20 |
2005-08-25 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
α7ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物
|
DE10211415A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Bicyclische N-Biarylamide
|
DE10211416A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Essig- und Propionsäureamide
|
JP2005537297A
(ja)
|
2002-08-01 |
2005-12-08 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
アルファ−7nachr活性を有する1h−ピラゾールおよび1h−ピロール−アザビシクロ化合物
|
WO2004019943A1
(en)
|
2002-08-30 |
2004-03-11 |
Memory Pharmaceuticals Corporation |
Anabaseine derivatives useful in the treatment of neurodegenerative diseases
|
GB0220581D0
(en)
|
2002-09-04 |
2002-10-09 |
Novartis Ag |
Organic Compound
|
EE05516B1
(et)
|
2002-09-25 |
2012-02-15 |
Memory@Pharmaceuticals@Corporation |
Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
|
EP1562959A2
(en)
*
|
2002-11-01 |
2005-08-17 |
Pharmacia & Upjohn Company LLC |
Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
|
US7238715B2
(en)
*
|
2002-12-06 |
2007-07-03 |
The Feinstein Institute For Medical Research |
Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
|
CA2507502C
(en)
|
2002-12-06 |
2011-11-29 |
North Shore-Long Island Jewish Research Institute |
Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
|
JP2006521345A
(ja)
*
|
2003-03-28 |
2006-09-21 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
ニコチン性アセチルコリン受容体の正のアロステリック調節剤
|
GB0310867D0
(en)
|
2003-05-12 |
2003-06-18 |
Novartis Ag |
Organic compounds
|
DE10334724A1
(de)
|
2003-07-30 |
2005-02-24 |
Bayer Healthcare Ag |
N-Biarylamide
|
DK1678172T3
(da)
|
2003-10-15 |
2010-04-06 |
Targacept Inc |
Azabicykliske forbindelser til lindring af smerte og behandling af sygdomme i centralnervesystemet
|
US20050137217A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
Spirocyclic quinuclidinic ether derivatives
|
ES2295973T3
(es)
|
2003-12-22 |
2008-04-16 |
Memory Pharmaceuticals Corporation |
Indoles, 1h-indazoles, 1,2-bencisoxazoles, y 1,2-bencisotiazoles, y preparacion y usos de los mismos.
|
EP1735306A2
(en)
|
2004-03-25 |
2006-12-27 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
|
US10912712B2
(en)
|
2004-03-25 |
2021-02-09 |
The Feinstein Institutes For Medical Research |
Treatment of bleeding by non-invasive stimulation
|
DE602005024677D1
(de)
|
2004-04-22 |
2010-12-23 |
Memory Pharm Corp |
Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
|
BRPI0510212A
(pt)
|
2004-05-07 |
2007-10-16 |
Memory Pharm Corp |
1h-indazóis, benzotiazóis, 1,2 - benzoisoxazóis, 1,2-benzoisotiazóis, e cromonas e a preparação e usos dos mesmos
|
AR049401A1
(es)
|
2004-06-18 |
2006-07-26 |
Novartis Ag |
Aza-biciclononanos
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
GB0424564D0
(en)
*
|
2004-11-05 |
2004-12-08 |
Novartis Ag |
Organic compounds
|
RU2418797C2
(ru)
|
2004-12-22 |
2011-05-20 |
Мемори Фармасьютиклз Корпорейшн |
Лиганды никотинового рецептора альфа-7, их получение и применение
|
US11207518B2
(en)
|
2004-12-27 |
2021-12-28 |
The Feinstein Institutes For Medical Research |
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
|
CN102793972A
(zh)
|
2004-12-27 |
2012-11-28 |
范因斯坦医学研究院 |
通过电刺激迷走神经治疗炎症性疾病
|
EP1917265B1
(en)
|
2005-08-22 |
2010-09-29 |
Targacept, Inc. |
HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
|
US8106066B2
(en)
|
2005-09-23 |
2012-01-31 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
|
GB0521508D0
(en)
|
2005-10-21 |
2005-11-30 |
Novartis Ag |
Organic compounds
|
US8316104B2
(en)
|
2005-11-15 |
2012-11-20 |
California Institute Of Technology |
Method and apparatus for collaborative system
|
GB0525672D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
GB0525673D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
TWI405763B
(zh)
*
|
2006-11-02 |
2013-08-21 |
Targacept Inc |
菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
|
CL2008000119A1
(es)
|
2007-01-16 |
2008-05-16 |
Wyeth Corp |
Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
|
RU2441868C2
(ru)
*
|
2007-02-09 |
2012-02-10 |
Астеллас Фарма Инк. |
Аза-кольцевое соединение с внутренним мостиком
|
TW200911808A
(en)
*
|
2007-07-23 |
2009-03-16 |
Astrazeneca Ab |
Novel compounds
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
US8391970B2
(en)
|
2007-08-27 |
2013-03-05 |
The Feinstein Institute For Medical Research |
Devices and methods for inhibiting granulocyte activation by neural stimulation
|
CN101883771A
(zh)
|
2007-10-01 |
2010-11-10 |
科门蒂斯公司 |
作为α7-烟碱乙酰胆碱受体配体用于治疗阿尔茨海默氏病的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
|
PT2254598E
(pt)
|
2008-02-13 |
2013-10-16 |
Targacept Inc |
Combinação de agonistas nicotínicos alfa 7 e antipsicóticos
|
WO2009146030A1
(en)
|
2008-03-31 |
2009-12-03 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation of t-cell activity
|
US9662490B2
(en)
|
2008-03-31 |
2017-05-30 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
|
CA2728675A1
(en)
|
2008-06-20 |
2009-12-23 |
Astrazeneca Ab |
Dibenzothiazepine derivatives and use thereof
|
ES2452484T3
(es)
|
2008-11-18 |
2014-04-01 |
Setpoint Medical Corporation |
Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
US20120094995A1
(en)
*
|
2009-01-28 |
2012-04-19 |
Astrazeneca Ab |
2-aza-bicyclo[2.2.1]heptane compounds and uses thereof
|
US8996116B2
(en)
|
2009-10-30 |
2015-03-31 |
Setpoint Medical Corporation |
Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
|
US9211410B2
(en)
|
2009-05-01 |
2015-12-15 |
Setpoint Medical Corporation |
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
EP2440284B1
(en)
|
2009-06-09 |
2018-09-12 |
Setpoint Medical Corporation |
Nerve cuff with pocket for leadless stimulator
|
FR2948368B1
(fr)
*
|
2009-07-21 |
2011-07-22 |
Servier Lab |
Nouveaux composes piperidiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
WO2014169145A1
(en)
|
2013-04-10 |
2014-10-16 |
Setpoint Medical Corporation |
Closed-loop vagus nerve stimulation
|
US9833621B2
(en)
|
2011-09-23 |
2017-12-05 |
Setpoint Medical Corporation |
Modulation of sirtuins by vagus nerve stimulation
|
EP2515996B1
(en)
|
2009-12-23 |
2019-09-18 |
Setpoint Medical Corporation |
Neural stimulation devices and systems for treatment of chronic inflammation
|
WO2011146511A1
(en)
|
2010-05-17 |
2011-11-24 |
Envivo Pharmaceuticals, Inc. |
A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
|
WO2012024616A1
(en)
|
2010-08-19 |
2012-02-23 |
Buck Institute For Age Research |
Methods of treating miild cognitive impairment (mci) and related discorders
|
EP2707094B1
(en)
|
2011-05-09 |
2016-02-03 |
Setpoint Medical Corporation |
Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
GB201111705D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Compounds and their use
|
GB201111704D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Novel compounds
|
JO3115B1
(ar)
|
2011-08-22 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مركبات بيريدازينون واستخدامها كمثبطات daao
|
US9572983B2
(en)
|
2012-03-26 |
2017-02-21 |
Setpoint Medical Corporation |
Devices and methods for modulation of bone erosion
|
AU2013259871A1
(en)
|
2012-05-08 |
2014-11-20 |
Forum Pharmaceuticals Inc. |
Methods of maintaining, treating or improving cognitive function
|
GB201209587D0
(en)
|
2012-05-30 |
2012-07-11 |
Takeda Pharmaceutical |
Therapeutic compounds
|
JOP20130273B1
(ar)
*
|
2012-09-11 |
2021-08-17 |
Genzyme Corp |
مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
|
WO2014122474A1
(en)
|
2013-02-07 |
2014-08-14 |
Takeda Pharmaceutical Company Limited |
Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
|
TWI649317B
(zh)
*
|
2013-03-15 |
2019-02-01 |
健臻公司 |
製備葡糖基神經醯胺合成酶抑制劑之方法
|
EP3010900B1
(en)
|
2013-06-21 |
2018-01-03 |
Takeda Pharmaceutical Company Limited |
1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
|
GB201314286D0
(en)
|
2013-08-08 |
2013-09-25 |
Takeda Pharmaceutical |
Therapeutic Compounds
|
GB201318222D0
(en)
|
2013-10-15 |
2013-11-27 |
Takeda Pharmaceutical |
Novel compounds
|
GB201320905D0
(en)
|
2013-11-27 |
2014-01-08 |
Takeda Pharmaceutical |
Therapeutic compounds
|
TW201613864A
(en)
|
2014-02-20 |
2016-04-16 |
Takeda Pharmaceutical |
Novel compounds
|
US9434724B2
(en)
|
2014-07-11 |
2016-09-06 |
Alpharmagen, Llc |
Quinuclidines for modulating alpha 7 activity
|
US11311725B2
(en)
|
2014-10-24 |
2022-04-26 |
Setpoint Medical Corporation |
Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
|
US11406833B2
(en)
|
2015-02-03 |
2022-08-09 |
Setpoint Medical Corporation |
Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
US10596367B2
(en)
|
2016-01-13 |
2020-03-24 |
Setpoint Medical Corporation |
Systems and methods for establishing a nerve block
|
US11471681B2
(en)
|
2016-01-20 |
2022-10-18 |
Setpoint Medical Corporation |
Batteryless implantable microstimulators
|
EP3405107B1
(en)
|
2016-01-20 |
2023-04-12 |
Setpoint Medical Corporation |
Control of vagal stimulation
|
WO2017127758A1
(en)
|
2016-01-20 |
2017-07-27 |
Setpoint Medical Corporation |
Implantable microstimulators and inductive charging systems
|
US10583304B2
(en)
|
2016-01-25 |
2020-03-10 |
Setpoint Medical Corporation |
Implantable neurostimulator having power control and thermal regulation and methods of use
|
GB201616839D0
(en)
|
2016-10-04 |
2016-11-16 |
Takeda Pharmaceutical Company Limited |
Therapeutic compounds
|
GB201619514D0
(en)
|
2016-11-18 |
2017-01-04 |
Takeda Pharmaceuticals Co |
Novel compounds
|
DE102017210141A1
(de)
|
2017-06-16 |
2018-12-20 |
Henkel Ag & Co. Kgaa |
Portion zur Bereitstellung tensidhaltiger Flotten
|
WO2019036470A1
(en)
|
2017-08-14 |
2019-02-21 |
Setpoint Medical Corporation |
TESTING TEST FOR STIMULATION OF NERVE WAVE
|
US11660443B2
(en)
|
2018-04-20 |
2023-05-30 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
|
US11260229B2
(en)
|
2018-09-25 |
2022-03-01 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
|
CN114829361B
(zh)
*
|
2019-11-15 |
2024-07-16 |
柳韩洋行 |
具有2,3-二氢-1h-茚或2,3-二氢苯并呋喃部分的衍生物或其药学上可接受盐及含其的药物组合物
|
WO2021096239A1
(en)
*
|
2019-11-15 |
2021-05-20 |
Yuhan Corporation |
Novel derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
|
JP2021138648A
(ja)
|
2020-03-04 |
2021-09-16 |
武田薬品工業株式会社 |
経口固形製剤
|
WO2021236977A1
(en)
|
2020-05-21 |
2021-11-25 |
The Feinstein Institutes For Medical Research |
Systems and methods for vagus nerve stimulation
|
EP4185267A1
(en)
|
2020-07-24 |
2023-05-31 |
Genzyme Corporation |
Pharmaceutical compositions comprising venglustat
|
MX2023012541A
(es)
*
|
2021-05-11 |
2023-11-03 |
Yuhan Corp |
Nuevos compuestos con actividad inhibidora contra la glucosilceramida sintasa o su sal farmaceuticamente aceptable, procedimientos para prepararlos y composiciones farmaceuticas que los contengan.
|
KR20240057364A
(ko)
*
|
2022-10-24 |
2024-05-02 |
주식회사유한양행 |
다이메틸-2,3-다이하이드로-1h-인덴 유도체의 신규 염 및 이의 제조방법
|
WO2024090919A1
(en)
*
|
2022-10-24 |
2024-05-02 |
Yuhan Corporation |
Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives
|